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Abstract
Background: PV and ET have high predisposition to thrombosis and 
recurrence of thrombosis. We determined VEGF, D-dimer and coag-
ulation activation markers in clinically stable patients and recurrence 
of thrombosis.
Methods: Thirty-five Indonesian patients diagnosed with PV and ET 
and under treatment for the disease were recruited. The following as-
says were performed: VEGF, D-dimer, fibrinogen, TAT-complex, vWF, 
β-TG and JAK2 V617F mutation. Data between patients who were 
clinically stable (n=20) and those with recurrent thrombosis (n=15) at 
the time of study was analysed.
Results: The mean age for PV/ET was 51.7 ± 14.9 years. Thrombosis 
episode was recorded for 94.3% (33/35) patients. Twenty (57.1%) 
clinically stable and 15 (42.9%) patients had recurrence of thrombosis. 
D-dimer (P=<0.001), fibrinogen (P=0.005) were statistically significant 
and VEGF (P=0.06) were seen in recurrence of thrombosis compared 
to clinically stable patients who had normal D-dimer. Elevated D-dimer 
seen in recurrence thrombosis was significantly correlated with VEGF 
(P=0.002) levels. Elevated VEGF were seen in 45% of clinically stable 
patients and 73.3% in recurrence of thrombosis. 
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Introduction
Polycythemia vera (PV) and essential thrombo-
cythemia (ET) are Philadelphia negative myelopro-
liferative neoplasms (MPNs) with cardinal features of 
an increased red cell mass in PV and high platelet 
count in ET (1, 2). They have high predisposition to 
thrombosis with a rate of major thrombosis as high 
as about 50% (3, 4). It is associated with JAK2V617F 
somatic mutation which carries an enhanced risk 
of thrombosis (5) but their role in thrombotic com-
plications is not entirely clear. Clinical factors (age, 
previous history of thrombotic events, JAK2 V617F 
somatic mutation (6) as well as leukocytosis, eryth-
rocytosis and thrombocytosis is associated with en-
hanced risk of thrombosis (7). Blood hyperviscosity 
causes high shear stress of vessel wall and accounts 
for chronic endothelial dysfunction, platelet and leu-
kocyte activation (8). Blood cell activation effects 
on the endothelium and plasma clotting factors are 
most likely the cause of thrombin formation in MPN 
have been reported (9). The mechanisms leading 
to thrombosis remain largely speculative, but are 
likely to be complex and multifactorial (10). Vascular 
endothelial growth factor (VEGF) a potent regulator 
of vascular permeability and angiogenesis is also an 
indirect procoagulant released by platelets (11, 12). 
Increased angiogenic activity has been reported in 
PV and ET (13, 14) and platelets are the major phys-
iological transporter of VEGF in blood (15). VEGF 
induces platelet activation and elevated levels stim-
ulate endothelial activation, enhance tissue factor 
synthesis and induce thrombin formation (16,17). In-
creased levels might be responsible for endothelium 
activation and for occurrence of a thrombotic event 
(18). The role of D-dimer assays in the diagnosis of 
patients with suspected deep vein thrombosis (DVT) 
has been extensively studied (19). It is a very useful 
diagnostic tool in the management of patients with 
suspected DVT and pulmonary embolism (PE) (20) 
and has been shown to have a high sensitivity and 
a high negative predictive value for DVT exclusion 
(21). It is a marker for hypercoagulability and links 
with venous as well as arterial thrombotic events 
and has been used to determine the hypercoagu-
lable state leading to thrombosis in PV and ET (22, 
23). The main strategy of management in PV and 
ET is to prevent thrombosis besides treating the dis-
ease (24).
The aim of the study is to determine VEGF, D-di-
mer and coagulation activation markers in Indone-
sian patients with polycythemia vera and essential 




The study received ethical approval from the 
Health Research Ethical Committee (197/KOMET/
FK/USU2010), Medical School, University of North 
Sumatra, Indonesia. Only patients diagnosed with 
PV and ET as defined by the WHO Protocol 2008 
Conclusions: Elevated D-dimer and fibrinogen with higher mean 
VEGF levels were seen in recurrence of thrombosis. VEGF and D-dimer 
measurements have clinical use in determining the risk of patients with 
vascular complications.
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(25) and who gave signed informed consent were 
admitted to the study. Patients were recruited be-
tween August 2010 and January 2011 from the 
hospitals in Medan, Indonesia: Adam Malik Hos-
pital, Dr Pirngadi Hospital, Herna Hospital, Imelda 
and Elizabeth Hospital. Recruitment of patients with 
either PV/ET on their visit to various hospitals and 
clinics was referred to the study. This include four-
teen patients who were diagnosed with recurrence 
of thrombosis at admission to the study and one 
patient who developed recurrence of thrombosis 
three days later.
A total of 45 patients were recruited and only 35 
patients (PV n=24 females n=3; ET n=11 females 
n=4) who fulfilled the inclusion criteria was admit-
ted into the study. Their age ranged between 14 
years and 79 years (mean 52.0 ± 15.1 years). Their 
characteristics are shown in Tables 1 and 2
Table 1. Characteristics of patients with PV and ET
PV ET PV/ET
N 24 11 35
Age mean (SD) years 54.6 (12.9) 45.3 (17.4) 51.7 (14.9)
Sex: Male/Female 21/3 7/4 28/7
History of thrombosis
Arterial 7 2 9
Venous 5 3 8
Arterial + venous 2 0 2
Microvascular 10 4 14
No history 0 2 2
At time of Study
Clinically stable 12 8 20
Clinical symptoms 12 3 15
Table 2.  Duration of diagnosis, JAK2 V617F mutation and history of thrombosis in clinically stable patients 
(A) and those who developed recurrent thrombosis (B).
A B
PV ET PV ET
Diagnosis (years ago) n
<1year 0 1 0 0
1-5 years 6 3 10 1
6-10 years 2 4 1 1
>10 years 4 0 1 1
JAK2 V617F mutation 6 4 7 2
History of thrombosis (years ago) n
1year ago 3 2 2 1
2 years ago 3 0 5 2
3  years ago 6 4 4 0
4-5 years ago 0 0 1 0
No history of thrombosis n 0 2 0 0
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Blood collection
Blood sampling was performed from a clean 
venepuncture using the Vacutainer system (Beck-
ton Dickenson, New Jersey, USA). About 8 mL of 
blood was collected and 3 mL gently mixed into 
citrate tubes (sodium citrate 0.109M) and the re-
mainder blood into plain tubes for serum collec-
tion. The citrated blood samples were double spun 
for 15 min each time at 2000g within an hour of 
blood collection. Serum and plasma samples were 
aliquoted and kept at -70° C until assayed. Blood 
sampling was performed only at admission to the 
study; in recurrence of thrombosis blood sampling 
was performed post-diagnosis at between 1 to 5 
days  (n=8), 10-20 days (n=5), and 30 days (n=1) 
except for one blood sampling was performed 3 
days before diagnosis. Most of the patients were 
on aspirin treatment regime. 
Laboratory assays
The following assays were performed: JAK2 
V617F mutation (IPSOGEN JAK2 MutantQuant Kit) 
was performed at the Molecular Diagnostic Centre, 
National University Health System (NUHS), Yong Loo 
Lin School of Medicine, National University of Sin-
gapore. Serum VEGF Immunoassay (R&D systems, 
Minneapolis, USA) and beta Thromboglobulin (βTG) 
(Asserachrome Kit, Stago, France). Von Willebrand 
Factor (VWF), in-house modified Elisa method us-
ing International Standard from National Biological 
Standards and Control (NIBSC), Potters Bar, Hert-
fordshire, UK, Fibrinogen (Clauss method) using in-
ternational standard from NIBSC, plasma D-dimer 
(Zymu D-dimer Kit, France). The above tests were 
performed at the Coagulation Laboratory, Depart-
ment of Obstetrics & Gynaecology, NUHS. 
Statistical Analysis
The Statistical Package for Social Sciences (SPSS17; 
SPSS Inc, Chicago, Il, USA) was used to perform the 
statistical analysis. Non-parametric Mann Whitney 
U test was performed together with independent 
t-test to evaluate patients under treatment who 
were clinically stable and those who developed 
clinical symptoms of recurrence of thrombosis at 
the time of admission to the study. Pearsons corre-
lation analysis was used to determine for correlation 
between elevated D-dimer against VEGF seen in re-
currence of thrombosis.  A P value of less than 0.05 
was considered statistically significant.
Results
In total, 35 patients who fulfilled the WHO de-
fined criteria for PV/ET was studied. Their charac-
teristics with history of thrombotic episodes are 
shown in Tables 1 and 2, VEGF and haemostatic 
parameters in Table 3. The statistics of evaluating 
PV/ET patients who were clinically stable and those 
who developed clinical symptoms of recurrence of 
thrombosis are shown in Table 4. The scatter plots 
of VEGF and D-dimer levels between clinically sta-
ble and recurrent thrombosis patients are shown 
in Figure 1 and the correlation between elevated 
D-dimer and VEGF levels in patients who developed 
recurrence of thrombosis in Figure 2.
Characteristics of patients studied 
The mean age of the patients was 51.7 ± 14.9 
years and ranged between 14 and 79 years. The ages 
between PV and ET with their history of thrombotic 
episodes are shown in Table 1. All patients were 
diagnosed with PV/ET between six months and ten 
years (n=29) and greater than ten years (n=6) (Ta-
ble 2). Past history of thrombosis was recorded be-
tween one to seventeen years post diagnosis of PV/
ET, one to five years ago in PV (100%, 24/24) and 
ET (81.8%, 9/11), of patients except for 2 patients 
(ET) who were clinically stable and diagnosed two 
and six years ago. Twenty patients were considered 
clinically stable (PV n=12; ET n=8) and 15 developed 
clinical symptoms of recurrence of thrombosis (PV 
n=12, ET n=3) at the time of study: microvascular 
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Table 3. VEGF and  haemostatic parameters in PV/ET patients (n=35)
Mean (SD)       Range     Normal Reference
VEGF pg/mL 202.4(164.1)   24.4 – 529.8 <115.0
D-dimer ng/mL 295.6 (179.4)  49.0  - 825.0 <400.0
TAT-complex µg/L     2.80 (1.74)     1.01 - 9.13 <2.0
vWF IU/mL     1.20 (0.43)     0.49 – 2.41 <1.5
Fibrinogen g/L     3.47 (1.71)     1.00 – 8.00 2.00 – 4.00
β-TG IU/mL              799.3 (883.8) 105.2 – 3987.0 <40.0
Table 4.  Statistics of parameters studied in PV/ET patients who are clinically stable (A) compared to those 





Age mean (SD) years  47.7 ( 17.7) 57.1 (7.5) 0.07
VEGF mean (SD) µg/mL 150.7 (134.0)  271.3 (179.2) 0.06
D-dimer mean (SD) ng/mL 199.4 ( 78.2)  423.9 (197.4) <0.001
TAT-complex mean (SD) µg/L 2.6 (2.1)  3.1 (1,2) 0.07
VWF mean (SD) IU/mL  1.10 (0.45)  1.34 (0.37) 0.05
Fibrinogen mean (SD) g/L  2.78 (0.89)  4.41 (2.11) 0.005
β-TG IU/mL 630.5 (531.5) 1024.0 (1191.0) 0.83
(B): MVD 5; DVT 3; CHD 2; stroke 4; PE 1
disease (MVD) 5, Deep Vein thrombosis (DVT) 3, 
Coronary heart disease (CHD) 2, stroke 4 and Pul-
monary Embolism (PE) 1. In clinically stable patients 
16 received aspirin 100 mg and one Clopidogrel 
75mg with phlebotomy treatment in 11 patients 
and 15 patients received both phlebotomy and as-
pirin at the time of blood sampling.  In patients who 
developed recurrence of thrombosis (n=15) seven 
received aspirin and one Clopidogrel while eleven 
had phlebotomy treatment. In 3 patients diagnosed 
with DVT (PV n=2, ET n=1) low molecular weight 
heparin was given in addition to aspirin (n=2) and 
clopidogrel (n=1).
VEGF and haemostatic parameters
No statistically significant differences in the pa-
rameters studied between PV and ET were seen 
and therefore their data were combined for anal-
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Figure 1:  D-dimer and VEGF levels in recurrence of thrombosis (n=15) and clinically 
stable states (n=20) in patients with PV/ET. 
Figure 2:  Correlation of elevated D-dimer against VEGF in recurrence of thrombosis. 
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ysis. Elevated levels of VEGF (mean 202.4±164.1 
pg/mL), TAT-complex (mean 2.80±1.74ug/mL) and 
β-TG (mean 799.3± 883.8 IU/mL) were evident in 
PV/ET patients compared to normal reference. Al-
though D-dimer, VWF and fibrinogen mean levels 
were within normal reference range their ranges 
were widely variable (Table 3). Elevated VEGF levels 
were seen in 20/35 (57.1%) patients, D-dimer 10/35 
(28.6%), Fibrinogen 9/35 (25.7%) and VWF 8/35 
(23.6%) patients. The age of patients at 65 years 
old and above was 20% (7/35).The reference ranges 
quoted was from the manufacturer’s normal refer-
ence and therefore, no age-matched to the study 
population was done (Table 3).
Statistics of parameters studied in PV/ET patients 
who were clinically stable (n=20) were compared 
to those who had developed clinical symptoms of 
recurrence of thrombosis (n=15) at admission to 
the study (Table 4). Recurrence of thrombosis oc-
curred in 13.3% (2/15) of patients at 65 years old 
and above. The mean age was higher for patients 
who experienced a recurrence of thrombosis (mean 
57.1 ±7.5 years vs mean 47.7 ±17.7 years) relative to 
those that were clinically stable but this observa-
tion did not reach statistical significance (P=0.07). 
Statistically significant elevated D-dimer (P= <0.001) 
and fibrinogen (P=0.005) were seen in patients with 
recurrence of thrombosis compared to patients who 
were clinically stable. Higher mean trends were 
seen for TAT-complex (P=0.07) and VWF (P=0.05) 
in recurrence of thrombosis but they did not reach 
statistical significance. No significant differences 
were also seen for VEGF and Beta-TG levels even 
though the levels were elevated above the normal 
reference in both groups (Table 4). Elevated VEGF 
levels were seen in 45.0% (9/20) of clinically stable 
patients and 73.3% (11/15) in patients with recur-
rence of thrombosis. Clinically stable patients had 
no elevated D-dimer levels whilst in the recurrence 
of thrombosis group 66.7% (10/15) patients had el-
evated levels (>400ng/mL).The scatter plot for VEGF 
and D-dimer in both groups is shown in Fig. 1.
Correlation between VEGF and D-dimer 
levels 
Statistically significant correlation between elevat-
ed D-dimer (10/15) and VEGF levels in recurrence of 
thrombosis group were seen (r=0.8540, P=0.002) 
(Fig. 2). D-dimer was not elevated in clinically sta-
ble patients even though 45% (9/20) had elevated 
VEGF levels (>115 pg/mL).
JAK2 V617F mutation
JAK2 V617F mutation was confirmed in 54.2% 
(13/24) patients with PV and in 54.5% (6/11) pa-
tients with ET. The overall mutation seen in PV/ET 
was 54.3%. No statistically significant differenc-
es in the parameters studied were seen between 
JAK2 V617F positive and negative patients except 
for VWF (P=0.04) in negative patients (mean 1.32 
± 0.35 IU/mL vs mean 1.10 ±0.47 IU/mL) in JAK2 
V617F positive mutation. 
Discussion
The thrombotic risk in PV and ET is more pro-
nounced in those over 60 years old and with a his-
tory of previous thrombosis as has been previously 
reported (3, 4). PV and ET have high predisposition 
to thrombosis with a rate of major thrombosis as 
high as about 50% (3, 4). Incidence of recurrent 
thrombosis was 5% in those below 65 years old 
and 10.9% in those above 65 years old (26) whilst 
another retrospective study the rate was 15% (27). 
Overall incidence of recurrence is 5.9% for those 
below 60 years old and risk factor of 1.7 fold in-
crease in those greater than 60 years old (28). In 
our study recurrence occurred in 42.9% (15/35) of 
which 14.7% (2/15) were over 65 years of age. VEGF 
measurement have been suggested to assess high 
and low risk PV patients (18). In this retrospective 
study of 35 patients diagnosed with PV/ET, 100% 
patients with PV had history of thrombosis between 
year one to seventeen  while in ET it was 81,8% 
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between year one to twelve from diagnosis, the 
incidence for PV/ET was 94.3% which was much 
higher than reported (3, 4). At admission to the 
study, 15 patients (42.9%), PV n=12, ET n=3 were 
reported to have developed recurrence of throm-
bosis between one and five years from last throm-
botic episode whilst the remaining 20 patients were 
clinically stable including two (ET) patients with no 
history of thrombosis. This recurrence of thrombosis 
was higher than reported (26, 8). A hypercoagulable 
state for this population was evident from elevat-
ed D dimer and fibrinogen levels seen in patients 
with recurrence of thrombosis, which is in agree-
ment with the study of Wautier and co-workers 
(9).  In support of this observation, D-dimer levels 
were not elevated in clinically stable patients. VEGF 
levels were elevated in 45.0% of patients who were 
clinically stable and 73.3% in patients who experi-
enced recurrence of thrombosis. The elevated levels 
are of concern as they are known as a pro-coagu-
lant, inducing endothelial activation and thrombin 
formation (16, 17). Markedly increased D-dimer was 
found in PV/ET and no differences of coagulation 
activation markers was found in relation to JAK2-
V617F mutational status (29). JAK2 V617F mutation 
was confirmed in 54.2% PV and 54.5% ET patients. 
We did not find any significant differences in the 
plasma levels of D-dimer and coagulation activation 
markers between JAK2 V617F positive and nega-
tive patients even though JAK2 V617F mutation 
associated with thrombosis (16, 17). Considerable 
variation of JAK2 V617F mutation frequency have 
been reported with PV of between 65- 97% and 
ET 23-57% (30) and PV 95%, ET 50-60% (31). The 
frequency of the mutation in PV patients (54.2%) 
in our study is rather low, whilst it was comparable 
to the published literature in ET patients (54.5%). 
The published reports for JAK2 V617F frequency 
are for Caucasian population and the frequency in 
Asians especially with PV need to be further investi-
gated. Possible variations in mutation discrepancies 
observed in PV include assay sensitivity, diagnostic 
accuracy and treatment effect (32) have been sug-
gested.
Conclusion
In conclusion, plasma VEGF levels were elevated 
(57.1%) in PV/ET patients relative to controls, al-
though the difference was not significant. Similarly, 
plasma D-dimer and fibrinogen levels were signifi-
cantly higher in patients with recurrence of throm-
bosis relative to clinically stable patients, whereas 
plasma VEGF levels were non-significantly elevated. 
Elevated plasma D-dimer seen in patients with re-
currence of thrombosis was found to correlate sig-
nificantly with elevated plasma VEGF levels. VEGF 
and D-dimer measurements have been used in clin-
ical practice to determine the risk of PV/ET patients 
with vascular complications.
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